PTSM: Pharmaceutical Technology Sourcing and Management
In a pilot program, Johnson & Johnson Supply Chain and AmerisourceBergen demonstrated how data can be transferred between two partners.
In 2016, the pharmaceutical manufacturer Johnson & Johnson Supply Chain (JJSC) and the distributor AmerisourceBergen launched a four-week pilot program to test GS1’s EPCIS standards and to see how effectively data could be transferred between the two partners. JJSC has been working on serialization for some time, and began shipping serialized product back in 2012, so both companies were fully connected, in terms of their IT, and they could try this approach with serialized product. The test simulated the real-world supply chain.
A DataMatrix barcode was applied containing a serialized global trade item number (GTIN), batch and lot number, and expiration data for each sellable unit (whether bottle, vial, or blister), and the units were packed into cases and loaded onto pallets, while downstream vision systems and scanners read the barcode to capture all the information. EPCIS recorded events associated with the GTIN, so that AmerisourceBergen could confirm receipt of each item sent by JJSC, automatically.
Results showed not only the viability of this approach, but its potential power. “It’s like electronic data interchange (EDI) on steroids,” says Mike Rose, vice-president, supply chain visibility at JJSC. “Over time, supply chain partners will be able to exchange a lot of critical data for additional value,” he says. The pilot ensured that all processes, from plant to warehouse and distribution channel to docks, were tracked. “It forced us to test all processes along with way. We got confirmation from our partner that everything fed back to them, from plant to distribution center, and that they were receiving relevant process data.” Rose expects to see return on investment in terms of improved inventory management and transparency in the future. “But for now, our focus remains on the patient first,” he says.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
3D Screen Printing: Enabling A New Generation of Complex Formulations
April 14th 20253D screen printing provides innovative drug development capabilities that are difficult or impossible to achieve with traditional methods, including complex multi-layered formulations, precision control over drug release profiles, and near-endless possibilities in the geometric shaping of dosage forms. In this article, learn how 3D screen printing offers unmatched flexibility to tailor formulations for specific therapeutic needs and redefines what’s possible in drug development and manufacturing.